U.S. patent application number 15/084342 was filed with the patent office on 2016-07-21 for compositions and minimally invasive methods for treating incomplete tissue repair.
The applicant listed for this patent is Allan Mishra. Invention is credited to Allan Mishra.
Application Number | 20160206657 15/084342 |
Document ID | / |
Family ID | 28794492 |
Filed Date | 2016-07-21 |
United States Patent
Application |
20160206657 |
Kind Code |
A1 |
Mishra; Allan |
July 21, 2016 |
COMPOSITIONS AND MINIMALLY INVASIVE METHODS FOR TREATING INCOMPLETE
TISSUE REPAIR
Abstract
Methods are described for using compositions containing
platelet-rich plasma for the treatment of a variety of tissue
lesions. Particularly, delivery of platelet-rich plasma to bone
tissue particularly a vertebral body or in combination with a bone
graft are disclosed.
Inventors: |
Mishra; Allan; (Menlo Park,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Mishra; Allan |
Menlo Park |
CA |
US |
|
|
Family ID: |
28794492 |
Appl. No.: |
15/084342 |
Filed: |
March 29, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11777968 |
Jul 13, 2007 |
9320762 |
|
|
15084342 |
|
|
|
|
10941124 |
Sep 15, 2004 |
7314617 |
|
|
11777968 |
|
|
|
|
10412821 |
Apr 11, 2003 |
6811777 |
|
|
10941124 |
|
|
|
|
60372682 |
Apr 13, 2002 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/137 20130101;
A61P 21/00 20180101; A61K 38/14 20130101; A61P 9/00 20180101; A61P
29/00 20180101; A61P 9/10 20180101; A61K 35/14 20130101; A61K 35/19
20130101; A61K 35/16 20130101; A61P 25/00 20180101; A61P 19/04
20180101; A61K 9/0019 20130101 |
International
Class: |
A61K 35/19 20060101
A61K035/19; A61K 31/137 20060101 A61K031/137; A61K 9/00 20060101
A61K009/00 |
Claims
1. A method of treating an injured tissue in an individual
comprising: determining a site of tissue injury in the individual;
and introducing a platelet-rich plasma composition into and around
the site of tissue injury, wherein the tissue comprises bone tissue
and wherein no exogenous activator is added to the composition
prior to its introduction into and around the site of injury.
2. The method of claim 1, wherein the bone tissue is fractured.
3. The method of claim 2, wherein the fracture is a compression
fracture.
4. The method of claim 1, wherein the bone tissue comprises a
vertebral body.
5. The method of claim 1, further comprising the step of titrating
the platelet-rich plasma to obtain a pH of about 7.3 to 7.5.
6. The method of claim 5, wherein the titration is performed using
a bicarbonate buffer.
7. The method of claim 1, wherein the platelet-rich plasma
composition comprises platelets obtained from the individual.
8. (canceled)
9. The method of claim 1, further comprising the step of mixing
into the platelet composition substantially simultaneously with the
introduction into and around the site of tissue injury, one or more
ingredients selected from the group consisting of thrombin,
epinephrine, collagen, calcium salts, and pH adjusting agents.
10-13. (canceled)
14. A method of treating a vertebral body that has sustained a
compression fracture comprising injecting a composition comprising
platelet-rich plasma into the vertebral body.
15. The method of claim 14, further comprising the use of a balloon
prior to injection.
16. The method of claim 14, wherein no exogenous activator is added
to the composition prior to its introduction into the vertebral
body.
17-21. (canceled)
22. The method of claim 4, wherein the vertebral body comprises a
fracture.
23. The method of claim 22, wherein the fracture is a compression
fracture.
24. The method of claim 1, wherein the platelet-rich plasma is
administered in combination with a bone graft.
Description
RELATED APPLICATIONS
[0001] This application is a divisional of U.S. application Ser.
No. 11/777,968, filed Jul. 13, 2007 which is a divisional of U.S.
application Ser. No. 10/941,124, filed Sep. 15, 2004, now U.S. Pat.
No. 7,314,617 which is a continuation of Ser. No. 10/412,821, filed
Apr. 11, 2003, now U.S. Pat. No. 6,811,777 which claims the
priority of Provisional Application No. 60/372,682, filed Apr. 13,
2002 which are all specifically incorporated herein by
reference.
[0002] Any and all applications for which a foreign or domestic
priority claim is identified in the Application Data Sheet as filed
with the present application are hereby incorporated by reference
under 37 CFR 1.57.
BACKGROUND OF THE INVENTION
[0003] 1. Field of the Invention
[0004] In one embodiment, the present invention is directed to a
method for the treatment of damaged tissue with a composition that
includes platelet-rich plasma. The treated tissue may be connective
tissue, cardiac muscle, skeletal muscle, disc material, vertebral
bodies, pancreas and other internal organs, brain tissue or spinal
cord tissue, or vascular tissue. In a preferred embodiment, the
tissue is connective tissue. The described compositions and methods
are also useful in wound healing and infections.
[0005] 2. Description of the Related Art
[0006] There is a need for treatment protocols for connective
tissue injuries which are refractory to standard treatments such as
anti-inflammatory medication, bracing, rest and physical therapy.
Injuries or other damage to flexible, relatively avascular
connective tissues (hereafter "connective tissue" or "connective
tissues") are known to take a very long time to heal (months or
even years). In many cases, injuries to connective tissues may
never heal properly, necessitating surgical intervention.
Connective tissue injuries and disorders have a significant impact
on society. The overall prevalence of these problems is
approximately 140 per 1000 persons in the United States, according
to a 1995 survey by the National Center for Health Statistics. The
same survey estimated the direct costs to be $88.7 billion and the
indirect costs estimated to be up to $111.9 billion for lost
productivity.
[0007] One example of a connective tissue disorder is lateral
epicondylitis. Lateral epicondylitis or "tennis elbow" is a
well-known sports medicine and orthopedic disorder. The pathology
underlying the disorder is related to overuse injury and
microtearing of the extensor carpi radialis brevis tendon at the
elbow. The body attempts to repair these microtears but the healing
process is incomplete in many cases. Pathologic specimens of
patients undergoing surgery for chronic lateral epicondylitis
reveal a disorganized angiofibroblastic dysplasia. This incomplete
attempt at repair results in degenerative, immature and avascular
tissue. Incompletely repaired tissue is weaker than normal tendon
tissue and lacks the strength to function normally. This tissue
also limits the patient by causing pain and negatively impacting
the patient's quality of life.
[0008] Similar incomplete repair may be present in other types of
connective tissue injuries or damage, such as patellar tendonitis
(Jumper's Knee), Achilles tendonitis (common in runners), and
rotator cuff tendonitis (commonly seen in "overhead" athletes such
as baseball pitchers), chronic injuries of the ankle ligaments
("ankle sprains"), or ligament tears.
[0009] The pathophysiology of the above-mentioned conditions have
been studied. Presently, many different non-operative and operative
treatments exist. The non-operative measures include rest, activity
modification, oral anti-inflammatory medication and cortisone
injections. Rest and activity modification may help patients with
some of these conditions, but there remains a significant clinical
population that are not reachable with these therapies. Despite
widespread use, oral anti-inflammatory medications have not proven
to be useful in controlled studies. Some studies further suggest
that non-steroidal medication may actually have an adverse effect
on the healing process for ligament injuries. Also, no acute
inflammatory cells have been found in pathologic samples of cases
of lateral epicondylitis. Cortisone injections are frankly
controversial in the treatment of tendinoses and are
contraindicated in acute ligament injuries. Several studies note an
improvement in patients treated with cortisone in short term follow
up. Results beyond one year, however, reveal a high symptom
recurrence rate and only an equivocal efficacy rate. These
injections also carry the risk of tendon rupture, infection, skin
depigmentation, subdermal atrophy and hyperglycemia in diabetic
patients. The operative measures include debridement and repair of
the associated pathologic tendons. However, open or arthroscopic
surgery has many potential complications such as deep infection,
damage to neurovascular structures, and scar formation. The surgery
is also expensive and carries the additional risks associated with
regional or general anesthesia.
[0010] What is needed are compositions and methods for solving the
problems noted above. Platelet-rich plasma (PRP) is an enriched
platelet-containing mixture, isolated from whole blood, which is
resuspended in a small volume of plasma. While whole blood may
contain about 95% red blood cells, about 5% platelets and less than
1% white blood cells, PRP may contain 95% platelets with 4% red
blood cells and 1% white blood cells. PRP can be combined with
activating agents such as thrombin or calcium which activate the
platelets to release their contents such as cytokinins and other
growth factors. PRP has been used in medicine, primarily in bone
grafting and dental implant applications and as part of a
composition to use as a surgical adhesive. For example, Landesberg
et al (U.S. Pat. No. 6,322,785) disclose an autologous platelet gel
that includes PRP for bone grafts and dental implants. The PRP is
activated by collagen and is applied topically to promote wound
healing.
[0011] Antanavich et al. (U.S. Pat. No. 5,585,007) disclose
preparation of PRP and use as a tissue sealant. Cochrum (U.S. Pat.
No. 5,614,214) discloses a biopolymer that optionally includes PRP
and its use to temporarily block arteries and veins. Gordinier et
al. (U.S. Pat. No. 5,599,558) disclose a platelet releasate
product, which includes platelets buffered to approximately pH 6.5,
for use in a topical application to wounds.
[0012] None of the prior art teach treatment of connective tissue
with PRP to promote tissue repair. Furthermore, Applicant has
discovered that PRP has even broader application in treating a wide
range of tissue injury and/or damage.
SUMMARY OF THE INVENTION
[0013] In one embodiment, the present invention is drawn to a
method of treating an injured tissue in an individual including the
steps of determining a site of tissue injury in the individual; and
introducing a platelet-rich plasma composition into and around the
site of tissue injury. In preferred embodiments, the tissue is
selected from the group consisting of connective tissue, cardiac
muscle, skeletal muscle, disc material, a vertebral body, brain,
spinal cord, and vascular tissue. In a preferred embodiment, the
tissue is a part of an internal organ. In a more preferred
embodiment, the internal organ is the pancreas. In a particularly
preferred embodiment, the tissue is a connective tissue.
[0014] In preferred embodiments the platelet-rich plasma is
titrated to obtain a pH of about 7.3 to 7.5. In a more preferred
embodiment, the titration is performed using a bicarbonate
buffer.
[0015] In preferred embodiments, the platelet-rich plasma
composition includes platelets obtained from the individual who is
to be treated with the platelet-rich plasma composition. In a
preferred embodiment, no exogenous activator is added to the
composition prior to its introduction into and around the site of
injury.
[0016] In some embodiments, the method includes the step of mixing
into the platelet composition substantially simultaneously with the
introduction into and around the site of tissue injury, one or more
ingredients including but not limited to thrombin, epinephrine,
collagen, calcium salts, and pH adjusting agents.
[0017] In one embodiment the present invention is drawn to a
platelet-rich plasma composition for the treatment of an injured
tissue which includes platelet-rich plasma; and a pH adjusting
agent, wherein the composition does not contain an activator of the
platelet-rich plasma. In a preferred embodiment, the pH of the
platelet-rich plasma composition is adjusted to a pH of about 7.3
to 7.5 with a pH adjusting agent. In a more preferred embodiment,
the pH adjusting agent is a bicarbonate buffer. Preferably, the
plasma used for the platelet-rich plasma is from an autologous
source.
[0018] In one embodiment, the present invention is drawn to a
method of making a platelet-rich plasma composition including the
steps of drawing blood from an individual; obtaining a plasma
fraction from the blood; isolating platelets from the plasma
fraction; resuspending the platelets in a reduced amount of plasma;
and adjusting the pH to provide a pH of 7.3 to 7.5 for the
resuspended platelets to provide a platelet-rich plasma
composition, wherein an activator of the platelet-rich plasma is
not added to the platelet-rich plasma composition.
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] These and other feature of this invention will now be
described with reference to the drawings of preferred embodiments
which are intended to illustrate and not to limit the
invention.
[0020] FIG. 1 shows the average visual analog pain scores at pre-op
and 6 months post-op.
[0021] FIG. 2 shows the average Mayo elbow scores at pre-op and 6
months post-op.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
[0022] The inventor has surprisingly discovered that certain
inventive platelet compositions are useful for the treatment of
several types of tissue damage or injury. As used herein, the term
"injury" is a broad term and is used in the ordinary sense to
refer, without limitation, to any tissue damage including a wound,
trauma or lesion or any tissue degeneration. In particular, the
inventive platelet compositions may be used to treat incomplete
repair of various connective tissues.
[0023] In one aspect, the invention relates to a method of treating
incomplete repair in a patient's connective tissue comprising:
obtaining a platelet composition; determining a lesion that
comprises the incomplete repair in the patient's connective tissue;
and minimally invasively introducing the platelet composition into
and around the lesion. In an aspect, the invention relates to the
method wherein the platelet composition is at or above
physiological pH. In an aspect, the invention relates to the method
wherein the platelet composition optionally includes platelet
releasate. In an aspect, the invention relates to the method
further comprising: mixing into the platelet composition one or
more of the ingredients selected from thrombin, epinephrine,
collagen, calcium salts, and pH adjusting agents. Also useful are
materials to promote degranulation or preserve platelets,
additional growth factors or growth factor inhibitors, small
molecule pharmaceuticals such as NSAIDS, steroids, and
anti-infective agents. In an aspect, the invention relates to the
method wherein the patient's connective tissue is selected from:
tendons, ligaments, joint capsules, and fascial tissues. In an
aspect, the invention relates to the method wherein obtaining the
platelet composition comprises: drawing blood from a human; and
centrifuging the blood to obtain a plasma-rich fraction. In an
aspect, the invention relates to the method wherein the platelet
composition comprises platelet-rich plasma. In an aspect, the
invention relates to the method with the proviso that the platelet
composition is substantially free from exogenous activators prior
to its introduction into and around the region of the incomplete
repair in the patient's connective tissue. In an aspect, the
invention relates to the method wherein the platelet composition
comprises platelets obtained from the patient.
[0024] The invention further relates to a method of treating
incomplete repair in a patient's connective tissue comprising:
obtaining a platelet composition; determining a lesion that
comprises the incomplete repair in the patient's connective tissue;
and introducing the platelet composition into and around the
lesion, with the proviso that substantially no activator is added
to the platelet composition prior to its introduction into and
around the lesion. The invention also relates to the method wherein
the platelet composition is minimally invasively introduced into
and around the lesion. The invention also relates to the method
wherein the platelet composition comprises platelet-rich plasma.
The invention also relates to the method further comprising: mixing
into the platelet composition substantially simultaneously with its
minimally invasive introduction into and around the lesion one or
more of the ingredients selected from thrombin, epinephrine,
collagen, calcium salts, and pH adjusting agents. Also useful are
materials to promote degranulation or preserve platelets,
additional growth factors or growth factor inhibitors, small
molecule pharmaceuticals such as NSAIDS, steroids, and
anti-infective agents. The invention also relates to the method
wherein the patient's connective tissue is selected from: tendons,
ligaments, joint capsules, and fascial tissues. The invention also
relates to the method wherein introducing the platelet composition
into and around the lesion comprises activating platelets in the
platelet composition through the action of collagen present in the
patient's connective tissue. The invention also relates to the
method wherein the platelet composition is at or above
physiological pH. The invention also relates to the method wherein
the platelet composition comprises platelets obtained from the
patient.
[0025] In yet another aspect, the invention relates to a
composition comprising: platelet releasate wherein the composition
is at a pH greater than or equal to physiological pH, and wherein
the composition comprises substantially no unactivated
platelets.
[0026] In a further aspect, the invention relates to a method of
treating lesions resulting from acute injury to or chronic
disorders of the Medial Collateral Ligament of the knee or elbow,
Extensor Carpi Radialis Brevis tendon, Anterior Talofibular
Ligament at the ankle, Achilles tendon, posterior tibial tendon,
patellar tendon, quadriceps tendon, Anterior Cruciate Ligament,
Posterior Cruciate Ligament, spinal ligaments, disc materials,
rotator cuff tendon, or biceps tendons comprising: obtaining a
platelet composition; determining a location of the lesion; and
introducing the platelet composition into and around the lesion,
with the proviso that substantially no activator is added to the
platelet composition prior to its introduction into and around the
lesion. In an aspect, the invention relates to the method wherein
the platelet composition is minimally invasively introduced into
and around the lesion. In an aspect, the invention relates to the
method wherein the platelet composition comprises platelet-rich
plasma. In an aspect, the invention relates to the method further
comprising: mixing into the platelet composition substantially
simultaneously with its minimally invasive introduction into and
around the lesion one or more of the ingredients selected from
thrombin, epinephrine, collagen, calcium salts, pH adjusting
agents. Also useful are materials to promote degranulation or
preserve platelets, additional growth factors or growth factor
inhibitors, small molecule pharmaceuticals such as NSAIDS,
steroids, and anti-infective agents. In an aspect, the invention
relates to the method wherein obtaining the platelet composition
comprises: drawing blood from a human; and centrifuging the blood
to obtain a plasma-rich fraction. In an aspect, the invention
relates to the method wherein the platelet composition is at or
above physiological pH. In an aspect, the invention relates to the
method wherein the platelet composition comprises platelets
obtained from the patient.
[0027] In a further aspect, the invention relates to a method of
treating lesions resulting from injury or chronic disorders of
cardiac muscle, skeletal muscle, organ systems, vascular tissue,
disc material, spinal bodies, spinal cord, and brain tissue
comprising: obtaining a platelet composition; determining a lesion
in need of treatment; and minimally invasively introducing the
platelet composition into and around the lesion. In an aspect, the
invention relates to the method wherein the platelet composition
optionally includes platelet releasate. In an aspect, the invention
relates to the method further comprising: mixing into the platelet
composition one or more of the ingredients selected from thrombin,
epinephrine, collagen, calcium salts, and pH adjusting agents. Also
useful are materials to promote degranulation or preserve
platelets, additional growth factors or growth factor inhibitors,
small molecule pharmaceuticals such as NSAIDS, steroids, and
anti-infective agents. In an aspect, the invention relates to the
method wherein obtaining the platelet composition comprises:
drawing blood from a human; and centrifuging the blood to obtain a
plasma-rich fraction. In an aspect, the invention relates to the
method wherein the platelet composition is at or above
physiological pH. In an aspect, the invention relates to the method
wherein the platelet composition comprises platelets obtained from
the patient.
[0028] In an aspect, the invention relates to the method wherein
the patient's connective tissue is selected from: tendons,
ligaments, joint capsules, and fascial tissues. In an aspect, the
invention relates to the method wherein obtaining the platelet
composition comprises: drawing blood from a human; and centrifuging
the blood to obtain a plasma-rich fraction. In an aspect, the
invention relates to the method wherein the platelet composition
comprises platelet-rich plasma. In an aspect, the invention relates
to the method with the proviso that the platelet composition is
substantially free from exogenous activators prior to its
introduction into and around the region of the incomplete repair in
the patient' damaged or injured tissue. In an aspect, the invention
relates to the method wherein the platelet composition comprises
platelets obtained from the patient.
[0029] The inventive platelet composition may be a biocompatible
composition that comprises unactivated platelets, activated
platelets, platelet releasate(s), or the like. In an embodiment,
the inventive platelet composition comprises platelet-rich plasma
(PRP).
[0030] The term "PRP" as used herein is a broad term which is used
in its ordinary sense and is a concentration of platelets greater
than the peripheral blood concentration suspended in a solution of
plasma, with typical platelet counts ranging from 500,000 to
1,200,000 per cubic millimeter, or even more. PRP is formed from
the concentration of platelets from whole blood, and may be
obtained using autologous, allogenic, or pooled sources of
platelets and/or plasma. PRP may be formed from a variety of animal
sources, including human sources.
[0031] Platelets are cytoplasmic portions of marrow megakaryocytes.
They have no nucleus for replication; the expected lifetime of a
platelet is some five to nine days. Platelets are involved in the
hemostatic process and release several initiators of the
coagulation cascade. Platelets also release cytokines involved with
initiating wound healing. The cytokines are stored in alpha
granules in platelets. In response to platelet to platelet
aggregation or platelet to connective tissue contact, as would be
expected in injury or surgery, the cell membrane of the platelet is
"activated" to secrete the contents of the alpha granules. The
alpha granules release cytokines via active secretion through the
platelet cell membrane as histones and carbohydrate side chains are
added to the protein backbone to form the complete cytokine.
Platelet disruption or fragmentation, therefore, does not result in
release of the complete cytokine.
[0032] A wide variety of cytokines are released by activated
platelets. Platelet derived growth factor (PDGF), transforming
growth factor-beta (TGF-b), platelet-derived angiogenesis factor
(PDAF) and platelet derived endothelial cell growth factor
(PD-ECGF) and insulin-like growth factor (IGF) are among the
cytokines released by degranulating platelets. These cytokines
serve a number of different functions in the healing process,
including helping to stimulate cell division at an injury site.
They also work as powerful chemotactic factors for mesenchymal
cells, monocytes and fibroblasts, among others. For the purposes of
this patent, the term "releasate" refers to the internal contents
of the platelet, including cytokines, which have the potential to
affect another cells' function.
[0033] Historically, PRP has been used to form a fibrin tissue
adhesive through activation of the PRP using thrombin and calcium,
as disclosed in U.S. Pat. No. 5,165,938 to Knighton, and U.S. Pat.
No. 5,599,558 to Gordinier et al., incorporated in their entirety
by reference herein. Activation results in release of the various
cytokines and also creates a clotting reaction within various
constituents of the plasma fraction. The clotting reaction rapidly
forms a platelet gel (PG) which can be applied to various wound
surfaces for purposes of hemostasis, sealing, and adhesion.
[0034] For instance, PG has been employed to assist with hemostasis
in spine surgery and in a rat liver laceration model. One recent
investigation showed that use of PG resulted in a significant
reduction in post-op narcotic use, a reduction in post-op
hemoglobin drop and faster return of functional range of motion
after total knee replacement. PG has also been used in wound
sealing. One study employed autologous PG as a sealant for
craniotomy procedures and noted success in 39 out of 40 patients.
PG has further been noted to augment bone healing. One controlled
randomized prospective trial of 88 patients revealed a 2 fold
increase in radiographic bone maturation and a 50% improvement in
histologic bone density when PG was used (Marx, et al., Oral Surg.
Oral Med. Oral Path. 1998, vol. 85(6): 638-646). In cardiac and
vascular surgery PG is being employed to reduce the incidence of
post-op wound dehiscence and infection (Kjaergard, et al., Eur J
Cardio-Thoracic Surg. 1996, vol 10: 727-733; Slater, et al., J
Ortho Res. 1995, vol 13: 655-663; Sumner et al. J. Bone Joint Surg.
(Am) 1995, vol 77:1135-1147; Sethi, et al. Presented at
International Society for the Study of Lumbar Spine, June
2001).
[0035] However, in none of the above applications and published
documents has it ever been disclosed that PRP could be used
surgically outside of the context of PG for any purposes other than
platelet transfusions to a patient. It is one unique feature of
this invention that platelets do not need to be activated prior to
their introduction into a patient during the practice of the
present invention.
[0036] In another embodiment, the inventive platelet composition
may comprise releasate from platelets, in addition to platelets
themselves. The releasate comprises the various cytokines released
by degranulating platelets upon activation. Many activators of
platelets exist; these include calcium ions, thrombin, collagen,
epinephrine, and adenosine diphosphate. Releasates according to the
invention may be prepared according to conventional methods,
including those methods described in U.S. Pat. No. 5,165,938 to
Knighton, and U.S. Pat. No. 5,599,558 to Gordinier et al.
[0037] One disadvantage of conventional releasate strategies
associated with the use of PRP as PG is the use of thrombin as a
preferred activator. In particular, much thrombin used in PG is
bovine thrombin, which can create problems due to contamination
issues regarding Creutzfeldt-Jakob disease. Many bovine materials
are suspect due to possible prion contamination, and so use of
bovine thrombin is disfavored in surgery. Human pooled thrombin is
likewise disfavored due to the potential of contamination with
various materials such as viruses, prions, bacteria and the like.
Recombinant human thrombin might also be used, but is quite
expensive.
[0038] It is a particular advantage of the present invention that
exogenous or extra activators need not be administered to a
patient. Collagen, a major component of connective tissues, is a
strong activator of platelets. Thus, when the inventive platelet
composition is introduced into and/or around connective tissue,
platelets in the platelet composition may bind to the collagen and
then be activated. This reduces or eliminates the need for
administering an exogenous activator such as thrombin. The
disadvantages of thrombin use have been noted above. Other strong
activators, such as calcium ions, can cause severe pain,
unintentional clotting, and other undesirable side effects. Thus,
in an embodiment of the invention, no or substantially no exogenous
activator is present or added as part of the inventive platelet
composition, or is used in the preparation of the inventive
platelet composition. Of course, exogenous activators may still be
employed if a physician determines that they are medically
necessary or desirable.
[0039] The platelet composition may be prepared using any
conventional method of isolating platelets from whole blood or
platelet-containing blood fractions. These include centrifugal
methods, filtration, affinity columns, and the like. If the
platelet composition comprises PRP, then conventional methods of
obtaining PRP, such as those disclosed in U.S. Pat. Nos. 5,585,007
and 5,788,662 both to Antanavich et al., incorporated herein by
reference in their entirety, may be utilized.
[0040] The platelet-rich plasma composition may be delivered to an
individual in need thereof by convention means which include
injection using a syringe, catheter, The platelet rich plasma
composition may also be delivered via a dermal patch, a spray
device or in combination with an ointment, bone graft or drug. It
may further be used as a coating on suture, stents, screws, plates
or some other implantable medical device. Finally, it may be used
in conjunction with a bioresorbable drug or device.
[0041] The site of delivery of the platelet-rich plasma composition
is at or near the site of tissue injury and/or damage. The site of
tissue injury or damage is determined by well-established methods
including imaging studies and patient feedback or a combination
thereof. The preferred imaging study used is determined by the
tissue type. Commonly used imaging methods include, but are not
limited to MRI, X-ray, CT scan, Positron Emission tomography (PET),
Single Photon Emission Computed Tomography (SPECT), Electrical
Impedance Tomography (EIT), Electrical Source Imaging (ESI),
Magnetic Source Imaging (MSI), laser optical imaging and ultrasound
techniques. The patient may also assist in locating the site of
tissue injury or damage by pointing out areas of particular pain
and/or discomfort.
[0042] Adjusting the pH of platelet compositions has been used to
prolong the storage time of unactivated platelets, as disclosed in
U.S. Pat. No. 5,147,776 to Koerner, Jr. and U.S. Pat. No. 5,474,891
to Murphy, incorporated by reference herein. pH may be adjusted
using a variety of pH adjusting agents, which are preferably
physiologically tolerated buffers, but may also include other
agents that modify pH including agents that modify lactic acid
production by stored platelets. Especially useful are those pH
adjusting agents that result in the pH of the platelet composition
becoming greater than or equal to physiological pH. In an
embodiment, the pH adjustment agent comprises sodium bicarbonate.
Physiological pH, for the purposes of this invention, may be
defined as being a pH ranging from about 7.35 to about 7.45. pH
adjusting agents useful in the practice of this invention include
bicarbonate buffers (such as sodium bicarbonate), calcium
gluconate, choline chloride, dextrose (d-glucose),
ethylenebis(oxyethylenenitrilo)tetraacetic acid (EGTA),
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), maleic
acid, 4-morpholinepropanesulfonic acid (MOPS),
1,4-piperazinebis(ethanesulfonic acid) (PIPES), sucrose,
N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES),
tris(hydroxymethyl)aminomethane (TRIS BASE),
tris(hydroxymethyl)aminomethane hydrochloride (TRIS.HCl), and urea.
In a preferable embodiment, the pH adjusting agent is a bicarbonate
buffer, more preferably, sodium bicarbonate.
[0043] For the purposes of this patent, the term "tissues" includes
but is not limited to cardiac and skeletal muscle, disc material,
vertebral bodies, internal organs, brain and spinal cord tissue,
vascular tissue such as arteries and veins and non-differentiated
tissue.
[0044] For the purposes of this patent, connective tissues comprise
tendons, ligaments, fascial tissues, and joint capsules. In a
preferable embodiment, connective tissues comprise the Medial
Collateral Ligament of the knee or elbow, Extensor Carpi Radialis
Brevis tendon (tennis elbow), Anterior Talofibular Ligament at the
ankle, Achilles tendon, Anterior Cruciate Ligament, Posterior
Cruciate Ligament, posterior tibial tendon, patellar tendon,
quadriceps tendon, rotator cuff tendon, and biceps tendons.
[0045] Incomplete repair, as it is used in the context of this
patent application, may be defined to mean repair that is
disorganized, substantially non-existent (such as in the case of an
unhealed tear), or otherwise pathological. Disorganized repair is
characterized by a disorganized angiofibroblastic dysplasia, with
degenerative, immature and avascular tissue. Such tissue is weaker
than normal connective tissue and lacks the strength to function
normally. This tissue also limits the patient by causing pain and
negatively impacting the patient's quality of life. Substantially
non-existent repair might occur in a situation where a connective
tissue is torn and does not heal properly subsequently to the tear.
Otherwise pathological repair may be any other type of repair in
which the tissue is not repaired to be substantially the same as
the tissue was before tissue repair was necessary.
[0046] It will be apparent to those skilled in the art that various
modifications and variations can be made to the present invention
without departing from the spirit or scope of the invention. Thus,
it is intended that the present invention cover the modifications
and variations of the present invention provided that they come
within the scope of the appended claims and their equivalents. The
following examples are illustrative of the present invention, and
are not intended to limit it.
EXAMPLES
Example 1
[0047] PRP was prepared using a centrifuge unit made by Harvest
(Plymouth, Mass.). (Similar units are available as The Biomet GPS
system, the Depuy Symphony machine and the Medtronic Magellan
machine.) Approximately 55 cc of blood was drawn from the patient
using a standard sterile syringe, combined with 5 cc of a citrate
dextrose solution for anticoagulation, and then spun down to
isolate the platelets according to the manufacturer's protocol.
These platelets were then resuspended in approximately 3 cc of
plasma. The resulting platelet rich plasma solution (PRP) was quite
acidic and was neutralized with using approximately 0.05 cc of an
8.4% sodium bicarbonate buffer per cc of PRP under sterile
conditions to approximately physiologic pH of 7.4. The PRP was not
activated through addition of exogenous activators. This PRP
composition is referred to herein as autologous platelet extract
(APEX).
Example 2
[0048] Fifty cc of whole blood is drawn from a patient, and then
prepared according to the method of Knighton, U.S. Pat. No.
5,165,938, column 3. The PRP is activated according to Knighton
using recombinant human thrombin. The degranulated platelets are
spun down and the releasate containing supernatant is recovered.
The releasate may be optionally pH adjusted to a pH of 7.4 using
sodium bicarbonate buffer.
Example 3
[0049] Thirty ml of whole blood were drawn from a patient. A
platelet composition was prepared according to Example 1 of U.S.
Pat. No. 5,510,102 to Cochrum, incorporated herein by reference in
its entirety, except that no alginate is added to the platelet
composition.
Example 4
[0050] A study of the effects of the PRP compositions described
herein was done using patients presenting with lateral
epicondylitis (tennis elbow) which had failed non-operative
treatment (anti-inflammatory medication, bracing rest and physical
therapy). The average duration of symptoms of these patients was
16.6 months. After obtaining informed consent, the patients were
formally enrolled in the study and randomly assigned to either the
APEX treatment group or control.
[0051] The patients were evaluated to obtain a visual pain score, a
Mayo Elbow Score, and grip strength. For the visual analog pain
score, zero equals "no pain" and 100 equals "the worst pain
possible." The Mayo elbow score is an overall function score with a
higher score indicating better overall function. The values of the
two scores were statistically evaluated using a paired sample T
test with significance set at p<0.05.
[0052] Each patient was then given 5 mg of Valium p.o. 30 minutes
prior to the inventive tendon procedure. Patients were then prepped
and draped in a sterile manner. A local anesthetic of 0.5%
bupivicaine with epinephrine was infiltrated into the skin,
subcutaneous structures and extensor carpi radialis brevis tendon.
Care was taken to keep the local anesthetic out of the elbow
joint.
[0053] Two to three minutes after administration of the local
anesthetic, approximately 3-5 cc of the APEX composition of Example
1 was introduced into the extensor carpi radialis brevis tendon at
the elbow via a 22 gauge needle. The control group received a
numbing shot (Bupivicaine). Multiple punctures into the tendon
approximately 0.5-1 cm from its origin were made. Promptly after
the minimally invasive introduction of either the APEX composition
of Example 1 or the numbing shot, the patient's arm was immobilized
at about 90% of flexion without elevation of the arm or hand. The
surgical area was then sterilely dressed and the patient asked not
to move their arm for 30 minutes. Each patients' neurovascular,
pain and function status was evaluated shortly after the injection,
and at 30 minutes following the end of the procedure. Each patient
was given oral narcotic pain medication as needed for the first
24-48 hours after the procedure. A formal postoperative stretching
and strengthening program may be initiated at 2-3 days after the
procedure. The visual pain score, Mayo Elbow Score, and grip
strength were all monitored post-procedure.
[0054] Tables 1 and 2 compare treated patients and control
preoperatively and at 8 weeks. 5 patients have been treated with
the PRP compositions of one aspect of the present invention (APEX)
while 3 patients received a numbing shot and provided a control.
The visual analog pain scores (Table 1) improved an average of 66%
for the PRP-treated group versus an average improvement of 20.4% in
the control group. The MAYO elbow score (Table 2) which tests elbow
function improved by an average of 44% in the PRP-treated group
compared to 30.5% in the control group.
TABLE-US-00001 TABLE 1 TENNIS ELBOW STUDY. Averaged Visual Analog
Pain Scores (0-100) for 5 patients treated with APEX and 3 control
patients preoperatively and at 8 week follow-up. Control APEX
(Bupivicaine) Preoperative 77 90 Postoperative-8 weeks 26 72 %
improvement 66% 20.4% n 5 3
TABLE-US-00002 TABLE 2 TENNIS ELBOW STUDY. Averaged Mayo Elbow
Scores for 5 patients treated with APEX and 3 control patients
preoperatively and at 8 week follow-up. Control APEX (Bupivicaine)
Preoperative 57.5 49 Postoperative-8 weeks 83 64 % improvement 44%
30.5% n 5 3
[0055] The improvement seen in the control may be attributed to the
observed phenomenon that insertion of a needle into a painful area
without drug delivery (dry needling), will result in some relief
from pain symptoms. However, the significantly larger improvements
in elbow function (Table 2) and pain level (Table 1) clearly
demonstrate the efficacy of the PRP treatments that are an aspect
of the present invention.
Example 5
[0056] The patient sample of Example 4 was again evaluated at 6
month time points. To date, five patients that are at least six
months post treatment with the APEX composition using the inventive
method described herein have been evaluated. The results are
outlined below in Tables 3 and 4. Average values for 5 patients
tested so far are shown.
TABLE-US-00003 TABLE 3 VISUAL ANALOG PAIN SCORE Preoperative Visual
Analog Pain Score Average: 77 Six Month Postoperative Visual Analog
Pain Score Average: 16 Improvement 79%
TABLE-US-00004 TABLE 4 MODIFIED MAYO ELBOW SCORE (A measure of
overall function) Preoperative Visual Analog Pain Score Average:
57.5 Six Month Postoperative Mayo Elbow Score Average: 88
Improvement 53%
[0057] The Visual Analog Pain Score (Table 3) represents an average
of 79% improvement in pain scores at six months. Table 4 represents
an average of 53% improvement in Mayo Elbow score at six months.
The data is graphically depicted in FIG. 1 (visual analog pain
scores) and FIG. 2 (Mayo elbow score improvement). Importantly, 4
of 5 patients are excellent (>90 by Mayo elbow score) and one
patient is in the good category. All patients were either fair or
poor prior to treatment. Even with this small sample, the
improvement was statistically significant (p values=<0.05).
Example 6
[0058] A patient presenting with Achilles tendinosis is given 5 mg
of Valium p.o. 30 minutes prior to the inventive tendon procedure.
The patient is then prepped and draped in a sterile manner. A local
anesthetic of 0.5% bupivicaine with epinephrine is infiltrated into
the skin, subcutaneous structures and Achilles tendon. Care is
taken to keep the local anesthetic out of the ankle joint.
[0059] Two to three minutes after administration of the local
anesthetic, approximately 3-5 cc of the APEX composition of Example
1 is introduced into the Achilles tendon just above the ankle via a
22 gauge needle. Multiple punctures into the tendon approximately
0.5-1 cm from its insertion are made. Promptly after the minimally
invasive introduction of the platelet composition of Example 1, the
patient's lower leg and foot are immobilized without elevation of
the leg. The surgical area is then sterilely dressed and the
patient is asked not to move their leg for 30 minutes. The
patient's neurovascular, pain and function status is evaluated
shortly after the injection, and at 30 minutes following the end of
the procedure. The patient is given oral narcotic pain medication
as needed for the first 24-48 hours after the procedure. The
Achilles tendon remains immobilized for one week following the
procedure, followed by an formal postoperative stretching and
strengthening program initiated at 8-10 days after the
procedure.
Example 7
[0060] A patient presenting with a medial collateral ligament tear
of the elbow is given 5 mg of Valium p.o. 30 minutes prior to the
inventive tendon procedure. The patient is then prepped and draped
in a sterile manner. A local anesthetic of 0.5% bupivicaine with
epinephrine is infiltrated into the skin, subcutaneous structures
and medial collateral ligament at the elbow. Care is taken to keep
the local anesthetic out of the elbow joint.
[0061] Two to three minutes after administration of the local
anesthetic, approximately 3-5 cc of the APEX composition of Example
1 is introduced into the medial collateral ligament at the elbow
via a 22 gauge needle. Multiple punctures into the ligament
approximately 0.5-1 cm from its origin are made. Promptly after the
minimally invasive introduction of the platelet composition of
Example 1, the patient's elbow and arm are immobilized at about 90%
of flexion without elevation of the arm or hand. The surgical area
is then sterilely dressed and the patient is asked not to move
their arm for 30 minutes. The patient's neurovascular, pain and
function status is evaluated shortly after the injection, and at 30
minutes following the end of the procedure. The patient is given
oral narcotic pain medication as needed for the first 24-48 hours
after the procedure. An optional formal post-operative stretching
and strengthening program may be initiated at 2-3 days after the
procedure.
Example 8
Cardiac Muscle
[0062] A patient presents with either an acute (i.e. heart attack)
or chronic dysfunction (i.e. congestive heart failure) of cardiac
muscle. An APEX composition is prepared as described in Example 1
Approximately 0.05 cc of an 8.4% sodium bicarbonate buffer per cc
of extract is used to raise the pH to or slightly above 7.4. The
extract is not activated through the addition of exogenous
agent(s).
[0063] The APEX is then introduced into the area of dysfunctional
cardiac muscle via a catheter. The APEX may also be combined with
an implantable device such as a stent.
Example 9
Skeletal Muscle
[0064] A patient presents with weakness or atrophy of skeletal
muscle. This could be the result of an injury or after a surgical
procedure. Using the technique of Example 1, an autologous platelet
extract (APEX) is obtained and buffered to physiologic pH.
[0065] The area of weakness or atrophy is identified and then after
using 0.5% bupivicaine with epinephrine as a local anesthetic, the
APEX is introduced into the muscle via a 22 g needle. This can be
done a single time or it may require multiple injections.
Postoperatively, the patient is started on a site specific
stretching and strengthening protocol.
Example 10
Disc Material/Vertebral Bodies
[0066] A patient presents with low back pain and either bulging or
black discs on an MRI scan. Using the technique of Example 1, an
autologous platelet extract (APEX) is obtained and buffered to
physiologic pH.
[0067] The disc in question is identified by X-ray guidance and
then the APEX is introduced into the disc space via small gauge
catheter. This procedure could be done alone or in combination with
a thermal/radiofrequency ablation procedure. The APEX could also be
injected into a vertebral body that has sustained a compression
fracture with or without the use of a balloon prior to
injection.
Example 11
Pancreas/Any Internal Organ
[0068] A patient presents with diabetes and poor insulin
production. Using the technique of Example 1, an autologous
platelet extract (APEX) is obtained and buffered to physiologic
pH.
[0069] Under CT guidance and conscious sedation, the APEX is
introduced via a small gauge catheter into the pancreas. The APEX
is then injected into the islet cells to stimulate repair of these
cells and thus restore insulin production.
Example 12
Brain/Spinal Cord
[0070] A patient presents with an acute neurologic deficit such as
a spinal cord injury or stroke. Using the technique of Example 1,
an autologous platelet extract (APEX) is obtained and buffered to
physiologic pH.
[0071] Under MRI guidance and conscious sedation, the APEX is
introduced into the area of injury or deficit. The APEX initiates
or assists with repair of the locally damaged cells.
Example 13
Vascular Tissue
[0072] A patient presents with an area of hypovascularity in his or
her lower extremities. The patient has a diagnosis of peripheral
vascular occlusive disease. Using the technique of Example 1, an
autologous platelet extract (APEX) is obtained and buffered to
physiologic pH.
[0073] The area of hypovascularity is blocked with bupivicaine and
then the APEX is introduced into either the muscle or soft tissue.
The APEX induces angiogenesis and new blood vessel formation.
Example 14
Wound Healing
[0074] A patient presents with a chronic wound that is not healing
properly. This could be a diabetic foot ulcer. Using the technique
of Example 1, an autologous platelet extract (APEX) is obtained and
buffered to physiologic pH.
[0075] The wound is carefully cleansed and debrided as needed. The
APEX is then carefully injected into and around the chronic wound
and its edges. It is held in place with an occlusive bandage or
combined with an ointment. This process may be repeated as needed
until the wound has healed.
Example 15
Neoplastic Tissue
[0076] A patient presents with either a benign or malignant tumor
or process. Using the technique of Example 1, an autologous
platelet extract (APEX) is obtained and buffered to physiologic pH.
The APEX can be used either in vivo or in vitro to initiate or
induce tumor cell death.
[0077] Specifically, the APEX is injected into a solid tumor with
CT or MRI guidance via a small catheter. Alternatively, cancer
cells after being grown in an APEX media could be reintroduced back
into the body to attack and kill the remaining tumor. Without
intending to be limited by theory, it is hypothesized that the APEX
media has either the ability to cause tumor cell apoptosis (cell
death) in vivo or it may have the ability to transform cancer cells
into normal cells.
Example 16
Infections
[0078] A patient presents with a superficial or deep infection.
Using the technique of Example 1, an autologous platelet extract
(APEX) is obtained and buffered to physiologic pH.
[0079] The area of the infection is identified and the APEX is then
directly applied or percutaneously introduced. This could be done
under local or general anesthesia and with or without imaging
guidance. The APEX typically has a concentrated number of white
blood cells along with platelets. This combination of white blood
cells and platelets either controls or eliminates an infection.
Example 17
Cell Cultures of Any Tissue
[0080] A researcher or clinician wishes to grow a cell culture of
either fibroblasts or osteoarthritic cartilage cells. Using the
technique of Example 1, an autologous platelet extract (APEX) is
obtained and buffered to physiologic pH.
[0081] The cells are then isolated and grown in a media rich in the
APEX in various conditions and dilutions. The APEX promotes cell
differentiation and production of proteins such as collagen. The
APEX may augment or promote the ability of the cells to transform
into normal cells. Without intending to be limited by theory, it is
hypothesized the APEX may convert the osteoarthritic cartilage
cells to a more functional cell line that is reinjected into a
diseased or injured joint. Alternatively, the APEX is directly
introduced into an osteoarthritic joint to reverse the course of
the disease. This is done under local anesthesia in a sterile
manner.
[0082] Finally, the APEX may be used to help grow and differentiate
any tissue or cell line in vivo or in vitro.
[0083] It will be understood by those of skill in the art that
numerous and various modifications can be made without departing
from the spirit of the present invention. Therefore, it should be
clearly understood that the forms of the present invention are
illustrative only and are not intended to limit the scope of the
present invention.
* * * * *